STOCK TITAN

Enliven Therapeutics: Collins exercises 5,000 options

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Enliven Therapeutics, Inc. Chief Medical Officer Helen Louise Collins exercised options to acquire 5,000 common shares at $2.48 per share on November 17, 2026. The reported option position after the exercise was 96,268 shares. Collins also sold 4,939 common shares at a weighted average $46.8313 per share and 61 RSU shares at a weighted average $47.5954 per share that day.

Insider Collins Helen Louise
Role CHIEF MEDICAL OFFICER
Sold 5,000 shs ($234K)
Approx. gross sale proceeds $234K
Approx. exercise cost $12K
Approx. pre-tax spread $222K
Type Security Shares Price Value
Exercise Stock Option (right to buy) F1, F6 5,000 $0.00 $0.00
Exercise Common Stock F1, F2 5,000 $2.48 $12K
Sale Common Stock F1, F3, F2 4,939 $46.8313 $231K
Sale Common Stock F1, F4, F5 61 $47.5954 $3K
Holdings After Transaction: Stock Option (right to buy) — 96,268 options (Direct); Common Stock — 25,000 shares (Direct)
Footnotes (6)
  1. F1. The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025.
  2. F2. Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
  3. F3. This transaction was executed in multiple trades at prices ranging from $46.455 to $47.435. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  4. F4. This transaction was executed in multiple trades at prices ranging from $47.5074 to $47.745. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  5. F5. These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
  6. F6. All of the shares subject to this option are fully vested and exercisable as of the date hereof.
Options exercised 5,000 options November 17, 2026
Exercise price $2.48 per share Options exercised November 17, 2026
Common shares sold 4,939 shares Weighted average sale price $46.8313 per share on November 17, 2026
RSU shares sold 61 shares Weighted average sale price $47.5954 per share on November 17, 2026
Option position after exercise 96,268 shares Reported following the November 17, 2026 exercise
Rule 10b5-1 trading plan regulatory
"pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
restricted stock units (RSUs) financial
"Certain of these securities are restricted stock units (RSUs)"
Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.
weighted average sale price financial
"reflects the weighted average sale price"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did Enliven Therapeutics (ELVN) Chief Medical Officer Helen Louise Collins sell?

Helen Louise Collins sold 4,939 common shares at a weighted average $46.8313 per share and 61 RSU shares at a weighted average $47.5954 per share on November 17, 2026. Both sales were made under a Rule 10b5-1 plan adopted October 19, 2025.

How many options did Enliven Therapeutics (ELVN) Chief Medical Officer Helen Louise Collins exercise?

Collins exercised options to acquire 5,000 common shares at $2.48 per share on November 17, 2026. The reported option position after the exercise was 96,268 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Collins Helen Louise

(Last)(First)(Middle)
C/O ENLIVEN THERAPEUTICS, INC.
205 PARK ROAD

(Street)
BURLINGAME CALIFORNIA 94010

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Enliven Therapeutics, Inc. [ ELVN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
CHIEF MEDICAL OFFICER
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/17/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/17/2026M(1)5,000A$2.4830,000(2)D
Common Stock11/17/2026S(1)4,939D$46.8313(3)25,061(2)D
Common Stock11/17/2026S(1)61D$47.5954(4)25,000(5)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$2.4811/17/2026M(1)5,000 (6)06/17/2031Common Stock5,000$096,268D
Explanation of Responses:
1. The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025.
2. Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
3. This transaction was executed in multiple trades at prices ranging from $46.455 to $47.435. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
4. This transaction was executed in multiple trades at prices ranging from $47.5074 to $47.745. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
5. These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
6. All of the shares subject to this option are fully vested and exercisable as of the date hereof.
/s/ Ben Hohl, by power of attorney11/19/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading